ticlopidine has been researched along with Nervous System Disorders in 9 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 9.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| " The prevalence of adverse events was assessed at each visit through a direct interview." | 6.78 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013) |
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 5.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| " Oral administration of ticlopidine inhibited the transient thrombocytopenia caused by ADP." | 3.66 | Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP. ( Butler, KD; White, AM, 1980) |
| "Thrombotic thrombocytopenic purpura is a thrombotic microangiopathy related to a severe deficiency of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13; activity <10%)." | 2.82 | Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. ( Azoulay, E; Benhamou, Y; Boisseau, P; Coppo, P; de Maistre, E; Delmas, Y; Galicier, L; Mariotte, E; Perez, P; Poullin, P; Provôt, F; Rondeau, E; Stepanian, A; Veyradier, A; Zouiti, F, 2016) |
| " The prevalence of adverse events was assessed at each visit through a direct interview." | 2.78 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, S | 1 |
| Lee, HY | 1 |
| Park, KW | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Kim, HS | 1 |
| Choi, DJ | 1 |
| Kim, MA | 1 |
| Oh, BH | 1 |
| Fornós-Garrigós, A | 1 |
| Orozco-Beltrán, D | 1 |
| Gil-Guillén, VF | 1 |
| Puig-Barberà, J | 1 |
| Fluixa, C | 1 |
| Fernández, A | 1 |
| Wang, C | 2 |
| Yi, X | 2 |
| Zhang, B | 1 |
| Liao, D | 1 |
| Lin, J | 2 |
| Chi, L | 1 |
| Mariotte, E | 1 |
| Azoulay, E | 1 |
| Galicier, L | 1 |
| Rondeau, E | 1 |
| Zouiti, F | 1 |
| Boisseau, P | 1 |
| Poullin, P | 1 |
| de Maistre, E | 1 |
| Provôt, F | 1 |
| Delmas, Y | 1 |
| Perez, P | 1 |
| Benhamou, Y | 1 |
| Stepanian, A | 1 |
| Coppo, P | 1 |
| Veyradier, A | 1 |
| Liu, P | 1 |
| Fu, C | 1 |
| Chen, Y | 1 |
| Fiorella, D | 1 |
| Litz, RJ | 1 |
| Gottschlich, B | 1 |
| Stehr, SN | 1 |
| Butler, KD | 1 |
| White, AM | 1 |
| Zauner, C | 1 |
| Funk, GC | 1 |
| Birnbacher, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial[NCT01830491] | Phase 4 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| ADAMTS13-related Prognostic Factors in Adult and Pediatric Thrombotic Thrombocytopenic Purpura[NCT00426686] | 153 participants (Actual) | Observational | 2006-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ticlopidine and Nervous System Disorders
| Article | Year |
|---|---|
Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Nervous System Diseases; Neuroprotective Agents; | 2010 |
3 trials available for ticlopidine and Nervous System Disorders
| Article | Year |
|---|---|
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; | 2013 |
Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke.
Topics: Acute Disease; Aged; Aspirin; Atherosclerosis; Clopidogrel; Female; Humans; Male; Nervous System Dis | 2015 |
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
Topics: ADAMTS13 Protein; Adult; Autoantibodies; Autoimmune Diseases; Clopidogrel; Cohort Studies; Cross-Sec | 2016 |
5 other studies available for ticlopidine and Nervous System Disorders
| Article | Year |
|---|---|
Appropriateness of clopidogrel use according to current recommendations.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clinical Audit; Clopidogrel; Electronic Health Rec | 2014 |
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M | 2016 |
Spinal epidural hematoma after spinal anesthesia in a patient treated with clopidogrel and enoxaparin.
Topics: Aged; Aged, 80 and over; Anesthesia, Spinal; Clopidogrel; Enoxaparin; Female; Fibrinolytic Agents; H | 2004 |
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
Topics: Adenosine Diphosphate; Animals; Antibodies; Arthus Reaction; Aspirin; Dipyridamole; Forssman Antigen | 1980 |
Platelet aggregation inhibition with ticlopidine in the treatment of stroke.
Topics: Acute Disease; Critical Care; Drug Eruptions; Drug Monitoring; Gastrointestinal Diseases; Humans; Ki | 2001 |